Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Purec, a Japan-based regenerative medicine spinout of Shimane University, secured ¥300m ($2.7m) in funding on Wednesday from photography and imaging company Fujifilm. Purec is working on a treatment for osteogenesis imperfecta, a group of genetic disorders that causes fragile bones that break even from mild trauma or without apparent impact. The investment will enable Fujifilm’s parent company, regenerative medicine producer Japan Tissue Engineering (J-Tec), to tap into the spinout’s technology. Purec and J-Tec will collaborate on the development of products.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).